triple glp-1/gip/glucagon receptor agonist Polyagonists Enable Increasingly Effective Treatment of Obesity and Diabetes | DZD Eat Less & Burn More

By increasing the synthesis of anti-inflammatory components, activating AMPK suppresses the production of pro-inflammatory cytokines and chemokines

Reduced Complications and Mortality Among patients who did develop acute pancreatitis, those receiving GLP-1 receptor agonists had significantly better outcomes

10.1038/s41598-020-75621-5 Summary Keywords incretinbased therapy, GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), T2D (type 2 diabetes), obesity, incretin receptors Citation Austin GO and Tomas A (2023) Variation in responses to incretin therapy: Modifiable and non-modifiable factors

#DrMedica #MedicalMCQ #GLP1 #Semaglutide #Liraglutide

doi: 10.1172/jci200215001

By this time, your provider at Internal Medicine and Family Practice has safely increased your dosage to a therapeutic level